Meta-analysis of EGLN3 expression in lung adenocarcinoma

doi:10.3877/cma.j.issn.1674-6902.2023.01.007

Abstract

Abstract:

Objective

EGLN3 is differentially expressed in many kinds of tumors. However, the role of EGLN3 in lung adenocarcinoma (LUAD) is not clear. The purpose of this study is to explore the role of EGLN3 in lung adenocarcinoma.

Methods

(1)535 LUAD samples and 59 normal samples were downloaded from Cancer Genome Map (TCGA) database to analyze the difference of EGLN3 expression between LUAD and normal lung tissues. (2)The expression level of EGLN3 and its clinical significance in LUAD were analyzed by R language. (3)The relationship between the expression of EGLN3 and the prognosis of LUAD was determined by Kaplan-Meier method, univariate and multivariate COX regression analysis and survival prediction diagram. (4)The biological pathways related to EGLN3 were screened by gene sets enrichment analysis (GSEA). (5)Cell experiment: Western blotting (WB) was used to verify the differential expression of EGLN3 in lung adenocarcinoma cells, and then EGLN3 was overexpressed and interfered, and CCK-8 proliferation test, scratch test and Transwell invasion test were carried out to determine the effect of its expression level on the proliferation, migration and invasion of lung adenocarcinoma cells.

Results

The expression level of EGLN3 in LUAD tissue was significantly higher than that in normal lung tissue. (2)The expression level of EGLN3 is related to the pathological stage of lung adenocarcinoma. The higher the pathological stage, the higher the expression level of EGLN3. (3)The expression of EGLN3 is an independent prognostic factor related to the overall survival (OS) of lung adenocarcinoma. The patients with high expression of EGLN3 had worse OS, disease specific survival (DSS) and progress free interval (PFI) than those with low expression of EGLN3. (4)Gene sets enrichment analysis predicted the possible signal pathways involved in EGLN3, including activation of MYC gene, epithelial mesenchymal transformation (EMT), DNA replication, cell cycle, mTORC1 pathway, G2/M checkpoint, E2F transcription process, p53 signal pathway, etc. (5) Cell experiment: The expression level of EGLN3 in LUAD cells was significantly higher than that in human bronchial epithelioid cells. CCK-8 proliferation test, scratch test and Transwell invasion test: the overexpression of EGLN3 promoted the proliferation, invasion and migration of lung adenocarcinoma cells, while the interference expression of EGLN3 inhibited the proliferation, invasion and migration of lung adenocarcinoma cells.

Conclusions

EGLN3 is highly expressed in lung adenocarcinoma cells, and its high expression indicates a poor prognosis of lung adenocarcinoma, which can be used as an independent factor to predict the prognosis of lung adenocarcinoma. The expression of EGLN3 can promote the proliferation, invasion and migration of lung adenocarcinoma cells.

Key words: EGLN3, Lung adenocarcinoma, Bioinformatics, Meta analysis

Shuo Yang, Hongming Ma, Xiaoting Guan, Zhengxian Chen. Meta-analysis of EGLN3 expression in lung adenocarcinoma[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 31-38.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2023.01.007

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2023/V16/I01/31

Figures/Tables 8

References 38

1	吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA: A Cancer J Clin, 2020, 70(1): 7-30.
3	Jiang F, Liang M, Huang X, et al. High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma[J]. Peer J, 2017, 9: e11697.
4	陈艳丽，王媛媛，张　勇，等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
5	中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志，2021, 43(6): 591-621.
6	Torre LA, Siegel RL, Jemal A. Lung cancer statistics.[J]. Adv Exper Med Biol, 2016, 893: 1-19.
7	Yue Y, Cui J, Zhao Y, et al. Circ_101341 deteriorates the progression of clear cell renal cell carcinoma through the miR- 411/EGLN3 axis[J]. Cancer Manag Res, 2020, 12: 13513-13525.
8	Xie L, Xiao K, Whalen EJ, et al. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL[J]. Sci Signal, 2009, 2(78): ra33.
9	Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J]. Cell, 2011, 145(5): 732-744.
10	Chen N, Rinner O, Czernik D, et al. The oxygen sensor PHD3 limits glycolysis under hypoxia via direct binding to pyruvate kinase[J]. Cell Res, 2011, 21(6): 983-986.
11	Xie L, Pi X, Mishra A, et al. PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response[J]. J Clin Invest, 2012，122(8): 2827-2836.
12	Yan B, Jiao S, Zhang HS, et al. Prolyl hydroxylase domain protein 3 targets Pax2 for destruction[J]. Biochem Biophys Res Commun, 2011, 409(2): 315-320.
13	Su Y, Loos M, Giese N, et al. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer[J]. Br J Cancer, 2010, 103(10): 1571-1579.
14	Schlisio S, Kenchappa RS, Vredeveld L, et al. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor[J]. Genes Development, 2008, 22(7): 884-893.
15	Jr. WGK, Bommi-Reddy A, Schlisio S. Inhibitors of egln3 activity for the treatment of neurodegenerative disorders: EP, EP1912637 A2[P]. 2010.
16	Li S, Rodriguez J, Li W, et al. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance[J]. Proc Natl Acad Sci U S A, 2019, 116(34): 16997-17006.
17	Wang Y, Li X, Liu W, et al. MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer[J]. Oncogene, 2019, 38(24): 4820-4834.
18	Pescador N, Cuevas Y, Naranjo S, et al. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene[J]. Biochem J, 2005, 390(1): 189-197.
19	蔡凤琳，邓靖宇. EGLN3在肿瘤发生发展中作用的研究进展[J]. 天津医科大学学报，2020, 26(6): 5.
20	Kim KH, Lee HH, Yoon YE, et al. Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker[J]. Investig Clin Urol, 2019, 60(6): 425-431.
21	Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci U S A, 2005, 102(43): 15545-15550.
22	Canzler S, Hackermüller J. multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data[J]. BMC Bioinformatics, 2020, 21(1): 561.
23	Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?[J]. Nat Rev Cancer, 2004, 4(11): 891-899.
24	Harris AL. Hypoxia-a key regulatory factor in tumour growth[J]. Nat Rev Cancer, 2002, 2(1): 38-47.
25	Semenza GL. Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer，2003, 3(10): 721-732.
26	Frey L, Klümper N, Schmidt D, et al. CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma[J]. Cancers, 2021, 13(9): 2177.
27	Melillo G. Targeting hypoxia cell signaling for cancer therapy[J]. Cancer Metastasis Rev, 2007, 26(2): 341-352.
28	Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene, 2010, 29(5): 625-634.
29	Wheaton WW, Chandel NS. Hypoxia.2.Hypoxia regulates cellular metabolism[J]. Am J Physiol Cell Physiol, 2011, 300(3): C385-C393.
30	Epstein AC, Gleadle JM, McNeill LA, et al. C．elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation[J]. Cell, 2001, 107(1): 43-54.
31	Huang J, Zhao Q, Mooney SM, et al. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1，PHD2，and PHD3[J]. J Biol Chem, 2002, 277(42): 39792-39800.
32	Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer[J]. Cancer Cell, 2005, 8(2): 155-167.
33	Lin L, Lin L, Cai J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation[J]. J Cell Biochem, 2020, 121(11): 4377-4385.
34	Xia YJ, Jiang XT, Jiang SB, et al. PHD3 affects gastric cancer progression by negatively regulating HIF1A[J]. Mol Med Rep, 2017, 16(5): 6882.
35	Mao K, You C, Lei D, et al. Potential regulation of glioma through the induction of apoptosis signaling via Egl-9 family hypoxia-inducible factor 3[J]. Oncol Lett, 2017, 13(2): 893-897.
36	Li J, Chen C, Li C, et al. Genome-wide knockout screen identifies EGLN3 involving in ammonia neurotoxicity[J]. Front Cell Dev Biol, 2022, 10: 820692.
37	Fu J. Catalytic-independent inhibition of cIAP1-mediated RIP1 ubiquitination by EGLN3[J]. Cell Signal, 2016, 28(2): 72-80.
38	Zhong C, Li S, Li J, et al. Polymorphisms in the Egl nine homolog 3 (EGLN3) and Peroxisome proliferator activated receptor-alpha (PPARα) genes and their correlation with hypoxia adaptation in Tibetan chickens[J]. PLoS One, 2018, 13(3): e0194156.

研究资料	变　量	EGLN3低表达(267)	EGLN3高表达(268)	P值
T分期	T1	95(17.9)	80(15)	0.546
	T2	140(26.3)	149(28)
	T3	22(4.1)	27(5.1)
	T4	9(1.7)	10(1.9)
N分期	N0	184(35.5)	164(31.6)	0.136
	N1	41(7.9)	54(10.4)
	N2	31(6)	43(8.3)
	N3	1(0.2)	1(0.2)
M分期	M0	185(47.9)	176(45.6)	0.378
	M1	10(2.6)	15(3.9)
临床分期	Ⅰ期	163(30.9)	131(24.9)	0.036
	Ⅱ期	55(10.4)	68(12.9)
	Ⅲ期	34(6.5)	50(9.5)
	Ⅳ期	11(2.1)	15(2.8)
初次治疗结果	PD	25(5.6)	46(10.3)	0.055
	SD	17(3.8)	20(4.5)
	PR	3(0.7)	3(0.7)
	CR	175(39.2)	157(35.2)
性别	女	148(27.7)	138(25.8)	0.409
	男	119(22.2)	130(24.3)
吸烟	否	36(6.9)	39(7.5)	0.734
	是	227(43.6)	219(42)
年龄	≤65	127(24.6)	128(24.8)	1.000
	>65	129(25.0)	132(25.6)

研究资料	变　量	EGLN3低表达(267)	EGLN3高表达(268)	P值
T分期	T1	95(17.9)	80(15)	0.546
	T2	140(26.3)	149(28)
	T3	22(4.1)	27(5.1)
	T4	9(1.7)	10(1.9)
N分期	N0	184(35.5)	164(31.6)	0.136
	N1	41(7.9)	54(10.4)
	N2	31(6)	43(8.3)
	N3	1(0.2)	1(0.2)
M分期	M0	185(47.9)	176(45.6)	0.378
	M1	10(2.6)	15(3.9)
临床分期	Ⅰ期	163(30.9)	131(24.9)	0.036
	Ⅱ期	55(10.4)	68(12.9)
	Ⅲ期	34(6.5)	50(9.5)
	Ⅳ期	11(2.1)	15(2.8)
初次治疗结果	PD	25(5.6)	46(10.3)	0.055
	SD	17(3.8)	20(4.5)
	PR	3(0.7)	3(0.7)
	CR	175(39.2)	157(35.2)
性别	女	148(27.7)	138(25.8)	0.409
	男	119(22.2)	130(24.3)
吸烟	否	36(6.9)	39(7.5)	0.734
	是	227(43.6)	219(42)
年龄	≤65	127(24.6)	128(24.8)	1.000
	>65	129(25.0)	132(25.6)

[1]	Pengcheng Ma, Wei Liu, Siping Zhang. Effect of joint capsular closure in arthroscopic treatment for femoroacetabular impingement syndrome [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 653-662.
[2]	Yuezhou Li, Kongxi Zhang, Xiaohong Li, Zhonghua Shang. Prognostic significance of PUM in gastric carcinoma based on bioinformatics analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 426-432.
[3]	Shengping Zhang, Qiong Deng, Ying Zhang, Jianwen Zhang, Hui Liang, Zhu Wang. Expression and significance of the orphan nuclear receptor HNF4α in renal clear cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 627-632.
[4]	Guojun Tang, Yude Hong, Chongyu Zhao, Liaoyuan Li. A novel prognosis model for papillary renal cell carcinoma based on Wnt-associated lncRNAs in TCGA database [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(03): 270-275.
[5]	Jing Qiu, Qing Huang. Hight expression of HJURP in lung adenocarcinoma and related with poor prognosis [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 495-499.
[6]	Lingfang Tan, Kebing Zhou. Identification of biomarkers associated with diagnosis of bronchial asthma based on integrated bioinformatics analysis [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(03): 329-334.
[7]	Nini Wang, Rongrong Chen, Qing Zhang, Chengshi Zhang, Donghui Cui, Jian Wu, Han Lei, Yunfeng Zhao. Primary mucinous adenocarcinoma of the lung: three cases report and literature review [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 190-194.
[8]	An Chen, Juan Feng, Zhenyu Yang, Xilin Du, Qiangshan Bai, Jikai Yin, Li Zang, Jianguo Lu. Analysis of CCN4 expression and its clinical significance in hepatocellular carcinoma based on bioinformatics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 702-707.
[9]	Weizhi Zhang, Lianxin Liu. Expression and significance of IPO7 in hepatocellular carcinoma based on bioinformatics analysis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 694-701.
[10]	Di Wang, Shaocheng Lyu, Jincan Huang. Pancreatic metastasis of lung adenocarcinoma with portal vein invasion: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 457-460.
[11]	Lei Wang, Daishan Jiang, Baofeng Zhu, Hanyu Jia, Junhua Shen, Yi Zhang. Bioinformatic analysis of genes related to nerve injury in heat stroke based on GEO database [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(02): 76-84.
[12]	Sugui Wang, Liyuan Huang, Fujin Jiang, Ziyu Wu, Xianyun Zhang, Qiang Li, Dali Yan. Role of HNRNPA2B1 in prostate cancer and screening of HNRNPA2B1-targeted active components of traditional Chinese medicine [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 731-736.
[13]	Minjie Zhang, Yaxi Wang, Shasha Duan, Yilu Shi, Wenyan Fu, haiyue Zhao, Xiaoshan Zhang. Bioinformatics screening of potential pathways and targets related to myocardial ischemia-reperfusion injury in rats based on GEO database [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 438-445.
[14]	Shihao Li, Zihao Li, Bo Dong, Chunli Wu, Bin Wu, Yinliang Sheng, Yu Qi. Effects of protein regulator of cytokinesis 1 on migration, invasion and proliferation of lung adenocarcinoma cell [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2023, 10(03): 164-175.
[15]	Xiao Chen, Changqing Liu, Hangcheng Zhou, Tian Li, Xiaohui Sun, Mingsheng Wu, Liangdong Xu, Meiqing Xu, Mingran Xie. Research progress of spread through air space on lung adenocarcinoma [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2023, 10(02): 126-130.

Please choose a citation manager

Content to export